Trial Profile
A Prospective randomized open label study to evaluate the response rate and toxicity of Gefitinib in the treatment of carcinoma cervix patients on chemoradiotherapy
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2020
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Cisplatin
- Indications Cervical cancer
- Focus Therapeutic Use
- 10 Jan 2020 Status changed from recruiting to discontinued.
- 05 Jan 2018 New trial record